Rotavirus immunization: Global coverage and local barriers for implementation

Vaccine

Volumn 35, Issue 12, 2017, Pages 1637-1644

  Lo Vecchio, Andrea ^a   Liguoro, Ilaria ^b   Dias, Jorge Amil ^c   Berkley, James A ^d   Boey, Chris ^e   Cohen, Mitchell B ^f   Cruchet, Sylvia ^g   Salazar Lindo, Eduardo ^h   Podder, Samir ⁱ   Sandhu, Bhupinder ^j   Sherman, Philip M ^k   Shimizu, Toshiaki ^l   Guarino, Alfredo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^e UNIVERSITY OF MALAYA   (Malaysia)

^f University of Alabama at Birmingham   (United States)

^g UNIVERSITY OF CHILE   (Chile)

^h UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

ⁱ Innovara   (United States)

^j BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^k HOSPITAL FOR SICK CHILDREN   (Canada)

^l JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Diarrhea; Immunization; Implementation; Rotavirus; Vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ANTI-VACCINATION MOVEMENT; ARTICLE; AUSTRIA; BANGLADESH; BELGIUM; BOTSWANA; BRAZIL; CAMBODIA; CANADA; CHILE; CHINA; DISEASE SEVERITY; DRUG COST; ESTONIA; ETHIOPIA; FINLAND; FRANCE; GERMANY; GHANA; HIGHEST INCOME GROUP; HUMAN; IMMUNIZATION; INDIA; INDONESIA; IRAQ; IRELAND; ISRAEL; ITALY; JAPAN; KENYA; LATVIA; LITHUANIA; LOW INCOME COUNTRY; MAJOR CLINICAL STUDY; MALAYSIA; MEXICO; NETHERLANDS; NIGERIA; NONHUMAN; NORWAY; PERU; POLAND; PORTUGAL; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; ROMANIA; ROTAVIRUS INFECTION; RUSSIAN FEDERATION; RWANDA; SENEGAL; SINGAPORE; SLOVENIA; SOUTH KOREA; SWITZERLAND; TAIWAN; TANZANIA; THAILAND; THIRD TRIMESTER PREGNANCY; TURKEY (REPUBLIC); UGANDA; UNITED KINGDOM; UNITED STATES; VACCINATION; ZAMBIA; GASTROENTERITIS; GLOBAL HEALTH; IMMUNOLOGY; QUESTIONNAIRE; VACCINATION COVERAGE;

GASTROENTERITIS; GLOBAL HEALTH; HUMANS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SURVEYS AND QUESTIONNAIRES; VACCINATION COVERAGE;

EID: 85013074741     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.01.082     Document Type: Article

References (31)

1. [1] Liu, L., Johnson, H.L., Cousens, S., et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379 (2012), 2151–2161.
2. [2] Albano, F., Bruzzese, E., Bella, A., et al. Rotavirus and not age determines gastroenteritis severity in children: a hospital-based study. Eur J Pediatr 166:3 (2007), 241–247.
3. [3] Tate, J.E., Burton, A.H., Boschi-Pinto, C., et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programs: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 136–141.
4. [4] http://sites.path.org/rotavirusvaccine/country-introduction-maps-and-spreadsheet [accessed on Aug 04 2016].
5. [5] WHO Weekly Epidemiological Record 2013;88(5):49–64.
6. [6] Ruiz-Palacios, G.M., Pérez-Schael, I., Velázquez, F.R., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354 (2006), 11–22.
7. [7] Linhares, A.C., Velázquez, F.R., Pérez-Schael, I., et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 371 (2008), 1181–1189.
8. [8] Vesikari, T., Karvonen, A., Puustinen, L., et al. Efficacy of RIX 4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 23 (2004), 937–943.
9. [9] Vesikari, T., Karvonen, A., Prymula, R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomized, double-blind controlled study. Lancet 370 (2007), 1757–1763.
10. [10] Patel, M.M., Clark, A.D., Glass, R.I., et al. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine 27 (2009), 2916–2922.
11. [11] Guarino, A., Winter, H., Sandhu, B., et al. Acute gastroenteritis disease: report of the FISPGHAN Working Group. J Pediatr Gastroenterol Nutr. 55 (2012), 621–626.
12. [12] Dubin, G., Toussaint, J.F., Cassart, J.P., et al. Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix: approach and outcome. Hum Vaccin Immunother 9:11 (2013), 2398–2408.
13. [13] Baylis, S.A., Finsterbusch, T., Bannert, N., Blümel, J., Mankertz, A., Analysis of porcine circovirus type 1 detected in Rotarix vaccine. Vaccine 29:4 (2011), 690–697.
14. [14] Parez, N., Giaquinto, C., Du Roure, C., et al. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis 14 (2014), 416–425.
15. [15] Prevention, A.C.I.P., Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 58 (2009), 1–25.
16. [16] Buttery, J.P., Danchin, M.H., Lee, K.J., et al., for the PAEDS/APSU Study Group. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 29 (2011), 3061–3066.
17. [17] de Oliveira, L.H., Danovaro-Holliday, M.C., Sanwogou, N.J., Ruiz-Matus, C., Tambini, G., Andrus, J.K., Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience. Pediatr Infect Dis J 30:suppl. 1 (2011), 61–66.
18. [18] Vesikari, T., Van Damme, P., Giaquinto, C., et al. European society for paediatric infectious diseases/European society for paediatric gastroenterology, hepatology, and nutrition evidence-based recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 46:suppl. 2 (2008), 38–48.
19. [19] Vesikari, T., Van Damme, P., Giaquinto, C., et al. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014. Pediatr Infect Dis J. 34:6 (2015 Jun), 635–643.
20. [20] Sabbe, M., Berger, N., Blommaert, A., et al. Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. Euro Surveill, 7(27), 2016, 21.
21. [21] Braeckman, T., Van Herck, K., Meyer, N., et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ, 345, 2012, e4752 [August 8].
22. [22] Hemming, M., Räsänen, S., Huhti, L., Paloniemi, M., Salminen, M., Vesikari, T., Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr 172:6 (2013), 739–746.
23. [23] Haber, P., Patel, M., Izurieta, H.S., et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 121:6 (2008), 1206–1212.
24. [24] Payne, D.C., Humiston, S., Opel, D., et al. A multi-center, qualitative assessment of pediatrician and maternal perspectives on rotavirus vaccines and the detection of Porcine circovirus. BMC Pediatr, 26(11), 2011 Sep, 83.
25. [25] van Hoek, A.J., Ngama, M., Ismail, A., et al. A cost effectiveness and capacity analysis for the introduction of universal rotavirus vaccination in Kenya: comparison between Rotarix and RotaTeq vaccines. PLoS One, 7(10), 2012, e47511.
26. [26] < http://www.gavi.org/support/nvs/rotavirus/> [accessed Aug 03 2016].
27. [27] Kannan Kutty, P., Pathmanathan, G., Salleh, N.M., Analysis of factors in response to rotavirus vaccination counselling in a private paediatric clinic. Med J Malaysia 65:2 (2010 Jun), 127–132.
28. [28] VENICE2. Finalised report on the decision making process, modalities of implementation and current country status for the introduction of human papilloma virus and rotavirus vaccination into national immunisation programmes in Europe; 2010 < http://venice.cineca.org/Venice2_WP3_Report_December2010.pdf> [accessed Feb 18, 2014].
29. [29] Plosker, G.L., Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Pharmacoeconomics 29 (2011), 989–1009.
30. [30] Blau, J., Sadr-Azodi, N., Clementz, M., et al. Indicators to assess national immunization technical advisory groups (NITAGs). Vaccine 31 (2013), 2653–2657.
31. [31] Takla A, Wichmann O, Carrillo-Santisteve P, Cotter S, Lévy-Bruhl D, Paradowska-Stankiewicz I, Valentiner-Branth P, D'Ancona F, the VENICE III NITAG Survey Group. Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014. Euro Surveill. 2015;20(9), doi: http://dx.doi.org/10.2807/1560-7917.ES2015.20.9.21049 [pii=21049].